Epigral has informed that the meeting of the Board of Directors of the Company is scheduled on 10/11/2025, to consider and approve Un-audited Financial Results (Standalone & Consolidated) of the Company for the Second Quarter and Half Year ended on 30th September, 2025.
The above information is a part of company’s filings submitted to BSE.